Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Generics Bulletin

Medtech Insight

Biosimilar Action Packages Low On US FDA Priority List For Redaction And Posting

Sep 24 2018

• By Sue Sutter

A redacted red ink stamp

Related Content

US FDA’s Streamlined Drug Approval Packages Shine Less Light On Sponsor Interactions

Sep 24 2018

Avoiding ‘Groundhog Day’: US FDA’s Biosimilar Action Plan Applies Lessons From Generic Competition

Jul 23 2018

Biosimilar Labeling: US FDA’s Final Guidance Means Status Quo For Sponsors

Jul 19 2018

Related Companies

Amgen, Inc.

AbbVie Inc.

Samsung Bioepis Co., Ltd.

Merck & Co., Inc.

Johnson & Johnson

Celltrion, Inc.

Pfizer Inc.

Viatris Inc.

Additional Topics

United States Biosimilars Drug Review Approvals Policy BioPharmaceutical

More from Biosimilars

More from Products

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window